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Background
The role of fluid resuscitation in the treatment of children with shock and life-
threatening infections who live in resource-limited settings is not established.
Methods
We randomly assigned children with severe febrile illness and impaired perfusion to 
receive boluses of 20 to 40 ml of 5% albumin solution (albumin-bolus group) or 0.9% 
saline solution (saline-bolus group) per kilogram of body weight or no bolus (control 
group) at the time of admission to a hospital in Uganda, Kenya, or Tanzania (stratum 
A); children with severe hypotension were randomly assigned to one of the bolus groups 
only (stratum B). All children received appropriate antimicrobial treatment, intravenous 
maintenance fluids, and supportive care, according to guidelines. Children with mal-
nutrition or gastroenteritis were excluded. The primary end point was 48-hour mor-
tality; secondary end points included pulmonary edema, increased intracranial 
pressure, and mortality or neurologic sequelae at 4 weeks.
Results
The data and safety monitoring committee recommended halting recruitment after 
3141 of the projected 3600 children in stratum A were enrolled. Malaria status (57% 
overall) and clinical severity were similar across groups. The 48-hour mortality was 
10.6% (111 of 1050 children), 10.5% (110 of 1047 children), and 7.3% (76 of 1044 
children) in the albumin-bolus, saline-bolus, and control groups, respectively (rela-
tive risk for saline bolus vs. control, 1.44; 95% confidence interval [CI], 1.09 to 1.90; 
P = 0.01; relative risk for albumin bolus vs. saline bolus, 1.01; 95% CI, 0.78 to 1.29; 
P = 0.96; and relative risk for any bolus vs. control, 1.45; 95% CI, 1.13 to 1.86; P = 0.003). 
The 4-week mortality was 12.2%, 12.0%, and 8.7% in the three groups, respectively 
(P = 0.004 for the comparison of bolus with control). Neurologic sequelae occurred 
in 2.2%, 1.9%, and 2.0% of the children in the respective groups (P = 0.92), and 
pulmonary edema or increased intracranial pressure occurred in 2.6%, 2.2%, and 1.7% 
(P = 0.17), respectively. In stratum B, 69% of the children (9 of 13) in the albumin-
bolus group and 56% (9 of 16) in the saline-bolus group died (P = 0.45). The results 
were consistent across centers and across subgroups according to the severity of 
shock and status with respect to malaria, coma, sepsis, acidosis, and severe anemia.
Conclusions
Fluid boluses significantly increased 48-hour mortality in critically ill children with 
impaired perfusion in these resource-limited settings in Africa. (Funded by the Med-
ical Research Council, United Kingdom; FEAST Current Controlled Trials number, 
ISRCTN69856593.)
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Rapid, early fluid resuscitation in patients with shock, a therapy that is aimed at the correction of hemodynamic abnor-
malities, is one component of goal-driven emer-
gency care guidelines. This approach is widely 
endorsed by pediatric life-support training pro-
grams, which recommend the administration of 
up to 60 ml of isotonic fluid per kilogram of body 
weight within 15 minutes after the diagnosis of 
shock.1 Children who do not have an adequate 
response to fluid resuscitation require intensive 
care for inotropic and ventilatory support.1 Sub-
stantial improvements in the outcomes of pediat-
ric septic shock have been attributed to this ap-
proach.2,3 Nevertheless, evidence regarding the 
criteria for intervention and the volume and type 
of fluid is lacking.4,5
In hospitals with poor resources in sub-Saharan 
Africa, in which intensive care facilities are rarely 
available, child-survival programs have largely 
ignored the role of triage and emergency care,6 
despite evidence of their cost-effectiveness.7,8 
Malaria, sepsis, and other infectious conditions 
cause major health burdens for children in sub-
Saharan Africa9,10 and are associated with high 
early mortality.11 Hypovolemic shock (a term in-
corporating all degrees of impaired perfusion) is 
common and increases mortality substantially.12-15 
However, World Health Organization guidelines16 
recommend reserving the practice of fluid resus-
citation for children with advanced shock (char-
acterized by a delayed capillary refill time of 
more than 3 seconds, weak and fast pulse, and 
cold extremities); consequently, it is not widely 
practiced. Most children in hospitals in sub-Saha-
ran Africa receive no specific fluid management 
apart from blood transfusion for severe anemia17 
or maintenance fluids.
The Fluid Expansion as Supportive Therapy 
(FEAST) study was designed to investigate the 
practice of early resuscitation with a saline bolus 
as compared with no bolus (control) and with an 
albumin bolus as compared with a saline bolus.
Me thods
Design and Treatment Protocol
We conducted this two-stratum, multicenter, 
open, randomized, controlled study in six clini-
cal centers in Kenya (one center), Tanzania (one 
center), and Uganda (four centers). In stratum A, 
we enrolled children without severe hypotension; 
children with severe hypotension (systolic blood 
pressure of <50 mm Hg in children younger than 
12 months of age, <60 mm Hg in children 1 to 
5 years of age, and <70 mm Hg in children older 
than 5 years of age) were enrolled in stratum B. 
In stratum A, eligible children were randomly as-
signed, in a 1:1:1 ratio, to rapid volume expan-
sion over the course of 1 hour with 20 ml of 
intravenous 0.9% saline solution per kilogram 
(saline-bolus group), 20 ml of 5% human-albu-
min solution per kilogram (albumin-bolus group), 
or no bolus (control group). Children in stratum B 
were randomly assigned to receive 40 ml of albu-
min bolus or saline bolus per kilogram. In both 
strata, the saline-bolus and albumin-bolus groups, 
but not the control group, received an additional 
20 ml of bolus solution per kilogram at 1 hour if 
impaired perfusion (see below) persisted. If se-
vere hypotension developed, the child was treated 
with 40-ml boluses of study fluid per kilogram 
(saline in the case of the control group); no cross-
over between bolus groups was permitted. Bolus 
volumes and rates were conservative relative to 
U.S. and European guidelines1 because we were 
concerned about the potential risk of pulmonary 
edema developing in children who were being 
treated in settings that lacked intensive care facili-
ties. The initial boluses were increased to 40 ml 
per kilogram (60 ml per kilogram in stratum B) 
after a protocol amendment in June 2010. The 
study protocol and a detailed description of study 
methods are available with the full text of this 
article at NEJM.org.
Study Oversight
The ethics committees at Imperial College, Lon-
don, Makerere University, Uganda, Medical Re-
search Institute, Kenya, and National Medical 
Research Institute, Tanzania, approved the pro-
tocol. In cases in which prior written consent 
from parents or guardians could not be obtained, 
provision was made for oral assent from a legal 
surrogate, followed by delayed written informed 
consent as soon as practicable.
An independent data and safety monitoring 
committee reviewed the interim analyses from 
the study twice a year. The Haybittle–Peto crite-
rion18 was the statistical guide that the commit-
tee used in considering a recommendation to stop 
or modify the trial. At the fifth interim review 
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of data on January 12, 2011, with data available 
from 2995 children, the independent data and 
safety monitoring committee recommended stop-
ping enrollment owing to safety concerns in the 
saline-bolus and albumin-bolus groups and be-
cause it was very unlikely that superiority of the 
bolus strategy over the control strategy would be 
shown.
Role of the Funding Sources
The study was funded by the Medical Research 
Council, United Kingdom; Baxter Healthcare do-
nated the 5% albumin and 0.9% saline solutions. 
Neither of those bodies, nor Imperial College, 
London, which held the legal responsibility for 
the trial, had any role in the design of the study, 
the collection, analysis, or interpretation of the 
data, or the writing of the manuscript. The cor-
responding author had full access to all trial data 
and assumes final responsibility for the decision 
to submit the manuscript for publication.
Study Population
Children were eligible for inclusion in the study 
if they were between 60 days and 12 years of age 
and presented with a severe febrile illness com-
plicated by impaired consciousness (prostration 
or coma), respiratory distress (increased work of 
breathing), or both, and with impaired perfusion, 
as evidenced by one or more of the following: 
a capillary refill time of 3 or more seconds, lower-
limb temperature gradient,19 weak radial-pulse 
volume, or severe tachycardia (>180 beats per 
minute in children younger than 12 months of 
age, >160 beats per minute in children 1 to 5 years 
of age, or >140 beats per minute in children older 
than 5 years of age) (Fig. 1). Exclusion criteria 
were severe malnutrition, gastroenteritis, non-
infectious causes of shock (e.g., trauma, surgery, 
or burns), and conditions for which volume ex-
pansion is contraindicated.
End Points
The primary end point was mortality at 48 hours 
after randomization. Secondary end points were 
mortality at 4 weeks, neurologic sequelae at 4 and 
24 weeks, episodes of hypotensive shock within 
48 hours after randomization, and adverse events 
potentially related to fluid resuscitation (pulmo-
nary edema, increased intracranial pressure, and 
severe allergic reaction). An end-point review 
committee, whose members were unaware of the 
treatment assignments, reviewed all deaths, neu-
rologic sequelae, and adverse events.
Randomization
Randomization was performed in permuted blocks 
of random sizes and was stratified according to 
clinical center. The trial statistician at the Medical 
Research Council Clinical Trials Unit, London, 
generated and kept all the randomization sched-
ules. The schedule for each center contained a 
list of trial numbers and the randomly assigned 
intervention. Trial numbers were kept inside 
opaque, sealed envelopes, which were numbered 
consecutively and opened in numerical order by a 
study clinician.
Study Procedures
Children were treated on general pediatric wards; 
assisted ventilation other than short-term bag-
and-mask support was unavailable. Training in 
triage and emergency pediatric life support was 
given to participating providers throughout the 
trial to optimize case recognition, supportive 
management, and adherence to the protocol. Ba-
sic infrastructural support was provided for emer-
gency care and for the monitoring of patients’ 
oxygen saturation and blood pressure, which was 
measured with the use of an automated blood-
pressure monitor. Children received intravenous 
maintenance fluids (2.5 to 4.0 ml per kilogram 
per hour); antibiotics; antimalarial, antipyretic, 
and anticonvulsant drugs; treatment for hypogly-
cemia (if the blood glucose was <2.5 mmol per 
liter [45 mg per deciliter]); and transfusion with 
20 ml of whole blood per kilogram over the course 
of 4 hours if the hemoglobin level was less than 
5 g per deciliter, according to national guidelines.
A structured clinical case-report form was 
completed at admission and at 1, 4, 8, 24, and 
48 hours. Hypovolemia, neurologic and cardio-
respiratory status, and adverse events — particu-
larly suspected pulmonary edema, increased in-
tracranial pressure, and allergic reaction — were 
recorded. Adverse events were reported to the 
Clinical Trials Facility in Kilifi, Kenya, within 
2 days and were verified against source docu-
ments by visiting monitors. At 4 weeks, assess-
ments of neurologic sequelae were performed, 
and these were reviewed by an independent cli-
nician, who was unaware of the treatment as-
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3170 Were enrolled
7838 Patients were assessed for eligibility
4668 Were excluded
2634 Did not meet inclusion criteria
1283 Met exclusion criteria
293 Declined to participate
458 Had other reasons
29 With severe hypotension were
randomly assigned within stratum B
13 Were assigned to the
albumin-bolus group
13 Received bolus
16 Were assigned to the
saline-bolus group
16 Received bolus
1050 Were assigned to the 
albumin-bolus group
1045 Received bolus
1 Withdrew before
intervention
4 Died before inter-
vention
1044 Were assigned to  
the control (no
bolus) group 
1 Received bolus of
saline
3141 Were randomly assigned
within stratum A
1047 Were assigned to the 
saline-bolus group
1041 Received bolus
2 Withdrew before
intervention
4 Died before inter-
vention
1 Did not fulfill eligibility
criteria
7 Were lost to follow-up
by 48 hr
2 Withdrew
5 Were taken from
hospital (and 48-hr
status unknown)
27 Were lost to follow-up
by 28 days
6 Withdrew
5 Were taken from 
hospital
16 Could not be 
located
1050 Were included
in analysis
2 Did not fulfill eligibility
criteria
8 Were lost to follow-up
by 48 hr
3 Withdrew
5 Were taken from
hospital (and 48-hr
status unknown)
23 Were lost to follow-up
by 28 days
4 Withdrew
5 Were taken from 
hospital
14 Could not be 
located
2 Were lost to follow-up
by 48 hr
1 Withdrew
1 Was taken from
hospital (and 48-hr
status unknown)
20 Were lost to follow-up
by 28 days
4 Withdrew
3 Were taken from 
hospital
13 Could not be 
located
1047 Were included
in analysis
1044 Were included
in analysis
Figure 1. Screening, Randomization, and Follow-up.
Of the 4668 children excluded after initial assessment for eligibility, 2634 with severe illness did not meet the inclusion criteria because 
they did not have at least one of the following: impaired perfusion, impaired consciousness, fever, or respiratory distress. A total of 1283 
children met exclusion criteria because they had evidence of severe acute malnutrition, defined as visible severe wasting or kwashiorkor 
(254 children); gastroenteritis (792); chronic renal failure, pulmonary edema, or other conditions in which volume expansion is contrain-
dicated (90); or noninfectious causes of severe illness (68); or because they had already received isotonic volume resuscitation (79). In 
addition, 458 children were not enrolled in the trial because they were unable to return for follow-up assessments (111 children), were 
enrolled in a different study (65), had been previously enrolled in the FEAST trial (17), or died before enrollment (11); because no fluid or 
blood or trial packs were available (47); or because of other reasons (181). The reason for noneligibility was missing in the case of 26 chil-
dren. During the intervention period, among children in stratum A, 1 child in the albumin-bolus group did not fulfill the eligibility criteria 
because the child had no fever or history of fever, and 2 children in the saline-bolus group did not fulfill the eligibility criteria, one be-
cause the child had severe hypotension and the other because the child did not have impaired perfusion.
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signments. Children with neurologic sequelae at 
4 weeks were reassessed at 24 weeks.
Statistical Analysis
The protocol specified two primary comparisons 
(saline bolus vs. control, and albumin bolus vs. 
saline bolus) with respect to the risk of death 
from any cause by 48 hours. In stratum A, the 
initial sample size of 2800 assumed a risk of 
death of 15% in the control group12; however, 
through a protocol amendment in June 2010, the 
sample size was increased to 3600 because the 
risk of death in the combined groups was lower 
than anticipated. We estimated that with a sam-
ple size of 3600 children, the study would have 
80% power to detect a 33% relative reduction in 
mortality with a saline bolus as compared with 
the control group and a 40% reduction with an 
albumin bolus as compared with a saline bolus, 
assuming a risk of death of 11% in the control 
group, at a two-sided alpha level of 0.05, adjusted 
for two comparisons with the use of a nominal 
alpha of 0.025.
All the analyses were performed according to 
the intention-to-treat principle, and all the sta-
tistical tests were two-sided. The three treatment 
groups were compared with respect to the pri-
mary end point (48-hour mortality) with the use 
of the chi-square test, and the relative difference 
among the groups was estimated by a calculation 
of the relative risk (the ratio of the proportion of 
children who died by 48 hours), adjusted for 
stratification according to clinical center and 
randomization date (before or after the protocol 
amendment) with the use of a Mantel–Haenszel 
type of adjustment.20 Kaplan–Meier plots show 
the time to death according to treatment group 
during the first 48 hours. The few children whose 
vital status was unknown (because of withdrawal 
of consent or loss to follow-up) were assumed to 
be alive at the end of the study. The same meth-
ods were used for the prespecified secondary 
comparisons, including pairwise comparisons of 
the risk of death or neurologic sequelae by 4 weeks 
and comparisons of bolus therapy (combined albu-
min bolus and saline bolus) with control (no bo-
lus) with respect to the risk of death at 48 hours 
and the risk of neurologic sequelae or death by 
4 weeks. Comparisons among the three groups 
with respect to the primary end point were also 
summarized for predefined subgroups according 
to coma status, positive or negative status for ma-
laria, presence or absence of severe anemia (hemo-
globin level <5 g per deciliter vs. ≥5 g per decili-
ter), age, sex, base deficit (≥8 mmol per liter vs. 
<8 mmol per liter), lactate level (≥5 mmol per liter 
vs. <5 mmol per liter), and date of randomization 
(before or after the protocol amendment).
R esult s
Study Patients
In stratum A, 3141 children were randomly as-
signed from January 13, 2009, through January 
13, 2011 — 1050 to the albumin-bolus group, 
1047 to the saline-bolus group, and 1044 to the 
control group. Three children who did not meet 
the eligibility criteria were included in all the 
analyses (Fig. 1). The baseline characteristics of 
the children were similar across the groups (Ta-
ble 1). The median age was 24 months (inter-
quartile range, 13 to 38); 62% had prostration, 
15% were comatose, and 83% had respiratory dis-
tress. The majority of children (52%) had more 
than one feature of impaired perfusion, most 
commonly severe tachycardia and cold extremi-
ties. Moderate-to-severe acidosis was present in 
51% of the children (1070 of 2079) and severe 
lactic acidosis (lactate ≥5 mmol per liter) in 39% 
(1159 of 2981). The mean (±SD) hemoglobin level 
was 7.1±3.2 g per deciliter, and the glucose was 
6.9±3.9 mmol per liter (124±70 mg per deciliter). 
Malaria was confirmed in 57% of the children 
(1793 of 3123), and 4% (106 of 2483) were posi-
tive for human immunodeficiency virus infection. 
Only 17 children (0.5%) were lost to follow-up for 
the primary end point — 7 in the albumin-bolus 
group, 8 in the saline-bolus group, and 2 in the 
control group. Vital status at 4 weeks was ascer-
tained in 97% (1023 of 1050), 98% (1024 of 1047), 
and 98% (1024 of 1044) of the children in the 
three groups, respectively. A total of 29 children 
were enrolled in stratum B. The median systolic 
blood pressure was 57 mm Hg (interquartile range, 
51 to 59) (Table 1 in the Supplementary Appendix, 
available at NEJM.org); no children in stratum B 
were lost to follow-up. In both strata, working di-
agnoses were reported by a clinician at 48 hours 
(Table 2 in the Supplementary Appendix).
Administered Fluids
A total of 99.5% of the children in the albumin-
bolus group (1045 of 1050 children) and 99.4% of 
the children in the saline-bolus group (1041 of 
1047) received the treatment to which they had 
been randomly assigned (Fig. 1). One child in the 
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control group received a saline bolus in the first 
hour (owing to hypotension). The median vol-
umes of all fluids (including blood) received dur-
ing the first and second hours were 20.0 ml per 
kilogram (interquartile range, 20.0 to 20.0) and 
4.5 ml per kilogram (interquartile range, 1.7 to 
16.2), respectively, in the albumin-bolus group; 
20.0 ml per kilogram (interquartile range, 20.0 
to 20.0) and 5.0 ml per kilogram (interquartile 
range, 1.7 to 16.0), respectively, in the saline-
bolus group; and 1.2 ml per kilogram (interquar-
tile range, 0 to 2.5) and 2.9 ml per kilogram (in-
terquartile range, 0.2 to 4.2), respectively, in the 
control group. Over the course of 8 hours, the 
median cumulative volume of fluid received was 
40.0 ml per kilogram (interquartile range, 30.0 
to 50.0) in the albumin-bolus group, 40.0 ml per 
kilogram (interquartile range, 30.4 to 50.0) in the 
saline-bolus group, and 10.1 ml per kilogram 
(interquartile range, 10.0 to 25.9) in the control 
group. A total of 1408 children received blood 
transfusions — 472 (45%) in the albumin-bolus 
Table 1. Baseline Characteristics of the Children.*
Variable
Albumin Bolus
(N = 1050)
Saline Bolus
(N = 1047)
No Bolus
(N = 1044)
Total
(N = 3141)
Demographic and anthropometric characteristics
Age — mo
Median 23 23 25 24
Interquartile range 14–37 13–37 14–40 13–38
Female sex — no. (%) 474 (45) 480 (46) 498 (48) 1452 (46)
Mid-upper-arm circumference ≤11.5 cm —  
no./total no. (%)
21/982 (2) 24/974 (2) 25/1003 (2) 70/2959 (2)
Findings at presentation
Axillary temperature >39°C — no. (%) 243 (23) 236 (23) 264 (25) 743 (24)
Hypothermia (temperature <36°C) — no. (%) 59 (6) 64 (6) 66 (6) 189 (6)
Respiratory distress — no./total no. (%) 874/1048 (83) 854/1045 (82) 857/1037 (83) 2585/3130 (83)
Respiratory rate — breaths/min 58±15 58±15 57±15 58±15
Oxygen saturation <90% — no. (%)† 249/1015 (25) 253/1008 (25) 257/1015 (25) 759/3038 (25)
Bradycardia (<80 beats/min) — no. (%) 13 (1) 7 (1) 10 (1) 30 (1)
Severe tachycardia — no. (%) 736 (70) 721 (69) 738 (71) 2195 (70)
Weak radial pulse — no. (%) 210 (20) 238 (23) 206 (20) 654 (21)
Capillary refill time — no. (%)
≥2 sec 712 (68) 720 (69) 673 (64) 2105 (67)
≥3 sec 263 (25) 299 (29) 257 (25) 819 (26)
Positive temperature gradient — no. (%)‡ 620 (59) 629 (60) 610 (58) 1859 (59)
Systolic blood pressure — mm Hg
Median 92 93 92 93
Interquartile range 85–101 85–101 86–101 85–101
Moderate hypotension — no./total no. (%)§ 66/1030 (6) 69/1036 (7) 57/1034 (6) 192/3100 (6)
Dehydration — no. (%)¶ 78 (7) 95 (9) 58 (6) 231 (7)
Severe pallor manifested in lips, gums, or inner eyelids 
— no. (%)
523 (50) 546 (52) 520 (50) 1589 (51)
Prostration — no./total no. (%)‖ 655/1048 (62) 667/1046 (64) 619/1044 (59) 1941/3138 (62)
Coma — no. (%)** 156 (15) 161 (15) 140 (13) 457 (15)
Convulsions during this illness — no./total no. (%) 414/1047 (40) 387/1045 (37) 371/1039 (36) 1172/3131 (37)
Hemoglobinuria (dark urine) — no. (%) 122 (12) 123 (12) 144 (14) 389 (12)
Jaundice visible to clinician — no. (%) 336 (32) 336 (32) 330 (32) 1002 (32)
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group, 487 (47%) in the saline-bolus group, and 
449 (43%) in the control group. Transfusion was 
initiated marginally earlier in the control group, 
but by 2 hours the proportion of children who 
received transfusions and the volumes of blood 
received were similar across all groups (Fig. 1 and 
Table 3 in the Supplementary Appendix).
End Points
By 48 hours, 111 of the children in the albumin-
bolus group (10.6%), 110 children in the saline-
bolus group (10.5%), and 76 children in the control 
group (7.3%) had died. The relative risk of death 
with a saline bolus versus no bolus was 1.44 (95% 
confidence interval [CI], 1.09 to 1.90; P = 0.01); 
the relative risk of death with an albumin bolus 
versus a saline bolus was 1.00 (95% CI, 0.78 to 
1.29; P = 0.96); and the relative risk of death with 
bolus therapy (combined albumin bolus and sa-
line bolus) versus no bolus was 1.45 (95% CI, 
1.13 to 1.86; P = 0.003) (Table 2); the absolute dif-
ference in risk was 3.3 percentage points (95% CI, 
1.2 to 5.3). There was no evidence of heterogeneity 
according to center (Fig. 2 in the Supplementary 
Appendix) or date of randomization before or after 
the protocol amendment (Fig. 2). In stratum B, 
9 of 13 children in the albumin-bolus group (69%) 
and 9 of 16 in the saline-bolus group (56%) died 
(relative risk with albumin bolus, 1.23; 95% CI, 
0.70 to 2.16; P = 0.45).
Table 1. (Continued.)
Variable
Albumin Bolus
(N = 1050)
Saline Bolus
(N = 1047)
No Bolus
(N = 1044)
Total
(N = 3141)
Laboratory assessments††
Positive for malaria parasitemia — no./total no. (%)‡‡ 590/1044 (57) 612/1042 (59) 591/1037 (57) 1793/3123 (57)
Hemoglobin — no./total no. (%)
<5 g/dl 323/1024 (32) 332/1015 (33) 332/1015 (33) 987/3054 (32)
>10 g/dl 231/1024 (23) 230/1015 (23) 244/1015 (24) 705/3054 (23)
Glucose — no./total no. (%)
<2.5 mmol/liter (45 mg/dl) 43/990 (4) 46/991 (5) 42/989 (4) 131/2970 (4)
<3.0 mmol/liter (54 mg/dl) 67/990 (7) 61/991 (6) 59/989 (6) 187/2970 (6)
Lactate ≥5 mmol/liter — no./total no. (%) 357/1000 (36) 407/989 (41) 395/992 (40) 1159/2981(39)
Base deficit ≥8 mmol/liter — no./total no. (%) 380/710 (54) 360/689 (52) 330/680 (49) 1070/2079 (51)
Severe acidemia (pH <7.2) — no./total no. (%) 71/712 (10) 73/694 (11) 65/685 (9) 209/2091 (10)
Hyperkalemia (potassium >6.5 mmol/liter) — no./ 
total no. (%)
67/686 (10) 68/687 (10) 65/670 (10) 200/2043 (10)
Positive for HIV antibody — no./total no. (%) 37/817 (5) 28/827 (3) 41/839 (5) 106/2483 (4)
Positive blood culture — no. of positive cultures/ 
total no. of cultures (%)
38/347 (11) 52/360 (14) 36/363 (10) 126/1070 (12)
Positive cerebrospinal fluid culture — no. of positive 
cultures/total no. of cultures (%)
2/94 (2) 4/102 (4) 4/96 (4) 10/292 (3)
* Plus–minus values are mean ±SD. HIV denotes human immunodeficiency virus.
† Oxygen saturation and pulse rate were recorded by a pulse oximeter.
‡ The temperature gradient was assessed by running the back of hand from the toe to the knee; a positive temperature gradient was defined 
as a notable temperature change from cold (dorsum of foot) to warm (knee).
§ Moderate hypotension was defined as a systolic blood pressure of 50 to 75 mm Hg in children younger than 12 months of age, 60 to 75 
mm Hg in children 12 months to 5 years of age, and 70 to 85 mm Hg in children older than 5 years of age, as measured with the use of 
an automated blood-pressure monitor.
¶ Dehydration was identified by the presence of sunken eyes or decreased skin turgor.
‖ Prostration was defined as the inability of a child older than 8 months of age to sit upright or the inability of a child 8 months of age or 
younger to breast-feed.
** Coma was defined as the inability to localize a painful stimulus.
†† Venous blood samples were obtained at admission for immediate analyses of pH level and potassium level with the use of a handheld 
blood analyzer (i-STAT, Abbott Laboratories); measurement of hemoglobin (HemoCue), blood glucose, and lactate levels; and HIV anti-
body testing. Denominators vary because data for some children were not available. Blood smears to test for malaria parasites were pre-
pared for immediate reading and subsequent quality control. Blood cultures at admission were obtained at certain centers only.
‡‡ The parasite that was identified was Plasmodium falciparum in every case except four: three in which P. vivax was identified and one in 
which P. ovale was identified.
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The risk of death 1 hour after randomization 
was similar in the three groups (1.2% in the al-
bumin-bolus group, 1.1% in the saline-bolus 
group, and 1.3% in the control group). Beyond 
1 hour, there was a persistent trend to higher 
mortality in the bolus groups as compared with 
the control group (Fig. 2A). Most deaths oc-
curred before 24 hours (259 deaths, 87%). Only a 
small number of deaths occurred after 48 hours, 
and there was no evidence that children in the 
control group had excess delayed mortality (Fig. 
2B). The excess mortality associated with the 
bolus groups as compared with the control group 
was consistent across all prespecified subgroups 
(Fig. 3), and there was no evidence supporting a 
benefit from bolus fluid infusion in any sub-
group. At 4 weeks, neurologic sequelae were 
noted in 22 children (2.2%) in the albumin-bolus 
group, 19 (1.9%) in the saline-bolus group, and 
20 (2.0%) in the control group (P = 0.92 for bolus 
vs. control) (Table 2). The 24-week follow-up as-
sessment is ongoing.
Suspected pulmonary edema occurred in 26 
children (14 in the albumin-bolus group, 6 in the 
saline-bolus group, and 6 in the control group) 
and increased intracranial pressure in 45 children 
(16 in the albumin-bolus group, 18 in the saline-
bolus group, and 11 in the control group) (P = 0.17 
for the comparison of bolus with control with 
respect to combined pulmonary edema and in-
creased intracranial pressure) (Table 2). Details 
of the review of deaths and targeted adverse 
events by the end-point review committee are 
provided in Tables 4A and 4B in the Supplemen-
tary Appendix.
Discussion
We evaluated the effect of resuscitation with bo-
lus fluids in children who presented to the hos-
pital with severe febrile illness and impaired per-
fusion, in order to generate practical data for 
resource-poor settings in sub-Saharan Africa in 
which malaria is endemic. Bolus-fluid resuscita-
tion with either albumin or saline, as compared 
with control, increased the absolute risk of death 
at 48 hours by 3.3 percentage points and the risk 
of death, neurologic sequelae, or both at 4 weeks 
by nearly 4 percentage points. There was no evi-
dence of a difference in either primary or second-
ary end points between the albumin-bolus and 
saline-bolus groups. Most deaths (87%) occurred 
before 24 hours; however, the predicted severe 
adverse effects of fluid overload (pulmonary ede-
ma or increased intracranial pressure) developed 
in few children. Our findings appear to be robust 
owing to the large number of children enrolled, 
the multinational nature of the sample, the small 
loss to follow-up, the concealment of treatment 
assignments, and the high rate of adherence to 
the assigned treatment. The results do not sup-
port the routine use of bolus resuscitation in se-
verely ill febrile children with impaired perfusion 
in African hospitals and also raise questions about 
its use in other settings.
Our large, controlled trial of fluid resuscita-
tion applied an international standard of prac-
tice (bolus-fluid resuscitation) and compared it 
with the local standard of care (no bolus-fluid 
resuscitation). It was conducted in typical African 
hospitals, which have no intensive care facilities. 
The inclusion criteria were broad, but children 
with gastroenteritis, severe malnutrition, or non-
infectious causes of shock were excluded, so re-
sults cannot be extrapolated to those groups. 
Few children were recruited to stratum B, which 
was reserved for children with severe hypoten-
sion, in whom randomization to a control group 
was considered to be unethical, and mortality 
was high in both bolus groups in that stratum.
Clinical differentiation of major causes of se-
vere illness in sub-Saharan Africa — in particular, 
severe malaria, sepsis, pneumonia, and menin-
gitis — is not possible at the time of admission 
to the hospital.21,22 However, recommendations 
regarding fluid resuscitation differ substantially 
among these conditions,16 and the practice of 
fluid resuscitation remains highly controversial 
in children with severe malaria.23-25 By including 
in our study children with these critical illnesses, 
our trial offered an efficient means of providing 
practical information for hospitals that have few 
diagnostic facilities. Mortality was lower than 
expected and than previously reported.12,14,22 
Consistent with other studies,22,26 mortality was 
lower in children with severe malaria than in the 
subgroup without malaria, but there was no evi-
dence that the increase in 48-hour mortality as-
sociated with boluses differed between the two 
subgroups. Although fluid boluses adversely af-
fected the outcome, important survival gains, 
across all the groups, may have resulted from 
training and implementation of triage, basic life-
support measures, and regular observation.
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We could not identify any subgroup in which 
fluid resuscitation was beneficial; this is remark-
able given that many of the baseline characteris-
tics of the children in this study are considered 
to be important criteria for bolus-fluid therapy, 
including moderate hypotension and severe met-
abolic acidosis.27 All the children received main-
tenance fluids and the standard of care recom-
mended by national guidelines. The receipt, and 
the timing of the receipt, of blood, quinine, and 
antibiotics were similar across groups; only bolus-
fluid resuscitation differed between the interven-
tion and control groups. The apparent lack of 
effect on early mortality (<1 hour), followed by 
an increasing negative effect over time, without 
amelioration of neurologic events, suggests a 
consistent adverse effect of bolus resuscitation 
with both saline and albumin. It has been 
thought that albumin has physiological benefits 
over saline, a hypothesis that was supported by 
the results of small trials involving children with 
severe malaria28-30 and a recent analysis of the 
sepsis subgroup31,32 of the adult Saline versus 
Albumin Fluid Evaluation trial (SAFE; Current 
Controlled Trials number, ISRCTN76588266). 
However, we observed no detectable differences 
between the bolus groups, providing evidence 
against a beneficial effect of albumin over saline. 
The excess mortality with fluid resuscitation was 
consistent across all subgroups, irrespective of 
physiological derangement or underlying micro-
bial pathogen, also raising fundamental ques-
tions about our understanding of the patho-
physiology of critical illness.
We had predicted that complications of fluid 
Figure 2. Kaplan–Meier Curves for Mortality.
Kaplan–Meier curves show the rate of death in the three 
study groups over the course of 48 hours from random-
ization (Panel A) and over the course of 4 weeks from 
randomization (Panel B).
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Figure 3. Mortality at 48 hours in Prespecified Subgroups.
The sizes of the boxes are proportional to the Mantel–Haenszel weights. The I2 statistic indicates the percentage of 
total variation that was due to heterogeneity.
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overload would develop in some children and 
incorporated mandatory clinical reviews to moni-
tor for pulmonary edema and increased intracra-
nial pressure. All reported adverse events were re-
viewed by the end-point review committee, whose 
members were unaware of the treatment assign-
ments; in addition the committee reviewed the 
records of all deaths for evidence of the presence 
of pulmonary edema or increased intracranial 
pressure. Few events were identified by this pro-
cess, and there was no evidence of differences 
among the groups; most deaths appeared to be 
attributable to the severity of the underlying con-
dition. The question therefore arises as to the 
reasons for the excess mortality among children 
receiving boluses. Our a priori hypothesis was 
that the benefit of bolus interventions would be 
greatest for the group that was at the highest 
risk, which included the children with the most 
severe hemodynamic and metabolic derange-
ment. However, although the degree of shock 
has been shown to be prognostic for an adverse 
outcome,12,14 our results suggest that it may not 
be a surrogate on the causal pathway for the ef-
fect of bolus resuscitation on survival. One could 
speculate that the vasoconstrictor response in 
shock confers protection by reducing perfusion to 
nonvital tissues and that rapid reversal with 
fluid resuscitation is deleterious. Alternatively, 
the adverse consequences of fluid boluses (even 
at low volumes) might act through other mecha-
nisms such as reperfusion injury, subclinical ef-
fects on pulmonary compliance, myocardial func-
tion, or intracranial pressure.33
In conclusion, the results of this study chal-
lenge the importance of bolus resuscitation as 
a lifesaving intervention in resource-limited 
settings for children with shock who do not 
have hypotension and raise questions regarding 
fluid-resuscitation guidelines in other settings 
as well.
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